feed,title,long_url,short_url
Benzinga,FactSet Registers 21% Revenue Growth In Q4 Aided By ASV Momentum; Margin Shrinks As Costs Weigh,https://benzinga.com/news/earnings/22/09/28962713/factset-registers-21-revenue-growth-in-q4-aided-by-asv-momentum-margin-shrinks-as-costs-weigh,https://bit.ly/3QZjT7L
Benzinga,"FDA Approves Lilly's Retevmo, the First and Only RET Inhibitor For Solid Tumor Indications",https://benzinga.com/general/biotech/22/09/28963082/fda-approves-lillys-retevmo-the-first-and-only-ret-inhibitor-for-solid-tumor-indications,https://bit.ly/3SrRlov
